The authors: Joachim Müller-Quernheim holds at present a chair of internal medicine/respiratory medicine and heads the Department of Pneumology, University Medical Center Freiburg, Germany. Antje Prasse is Assistant Professor and head of the outpatient clinic of the Department of Pneumology, University Medical Center Freiburg. The immunopathogenesis of diffuse parenchymal lung diseases is the main interest of both authors, and they have published several original contributions in the field of the aforementioned research topic.
Non-invasive biomarkers in pulmonary fibrosis
Article first published online: 17 AUG 2009
© 2009 The Authors. Journal compilation © 2009 Asian Pacific Society of Respirology
Volume 14, Issue 6, pages 788–795, August 2009
How to Cite
PRASSE, A. and MÜLLER-QUERNHEIM, J. (2009), Non-invasive biomarkers in pulmonary fibrosis. Respirology, 14: 788–795. doi: 10.1111/j.1440-1843.2009.01600.x
SERIES EDITORS: MARTIN KOLB AND GERARD COX
- Issue published online: 17 AUG 2009
- Article first published online: 17 AUG 2009
- Received 10 March 2009; invited to revise 6 April 2009; revised 7 May 2009; accepted 17 June 2009.
- collagen vascular disease;
- interstitial lung disease;
- pulmonary fibrosis
The practise of modern medicine is unthinkable without biological markers, and their adoption is now established in various clinical settings. Pulmonary fibrosis occurs in a heterogeneous group of diseases. IPF is the most frequent fibrotic lung disease and has a poor prognosis. Despite the heterogeneity in underlying diseases multiple common mechanism resulting in pulmonary fibrosis are documented. In this context, several biomarkers for pulmonary fibrosis have been described. Some substances are produced by alveolar epithelial cells such as surfactant proteins A and D, the glycoprotein Krebs von den Lungen 6 Antigen, while others are derived from macrophages such as CCL18. Most recently, increased fibrocyte counts were proposed as a marker of acute exacerbation in IPF. None of these markers is established in clinical practise so far. Studies regarding the clinical value of biomarkers in pulmonary fibrosis are hampered by the fact that fibrotic lung diseases are uncommon and variable in course. However, some markers are clearly promising, and as a spin-off the analysis of some of these in samples from recently finished pharmacological multicentric studies might give urgently needed information regarding their clinical value.